Shareholders approve 2.95M share increase under MaxCyte 2022 Equity Plan; AIM delisting also approved

MAXCYTE, INC.

Stockholders approved Amended 2022 Plan, increasing share reserve by 2,950,000 shares (74.1M for, 6.5M against).
Proposal to cancel admission to AIM London Stock Exchange passed with 82.9M votes in favor.
Elected Class I directors: Maher Masoud (69.8M for), Yasir Al-Wakeel (58.9M), Rekha Hemrajani (59.1M).
Ratified CohnReznick LLP as independent auditor for fiscal year 2025 (87.0M for).
Adjournment proposal deemed moot as all other proposals passed.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.